2023-01-31 09:00 Regulatory
Biovica, active in cancer diagnostics, today announces that results clinically validating the DiviTum® TKa assay have been published in the scientific journal Biomarkers. The results, from an analysis of samples and clinical data from the SWOG S0226...
2022-12-15 08:00 Regulatory Interim
Successful capital acquisition paves the way for launch in the USA Significant events during the second quarter Significant events after the end of the period Webcast: When: 15 December 2022 at 15.00 CET Where: registration via lyyti Broadcast language...
2022-12-13 22:00 Regulatory
Biovica, active in cancer monitoring, today announces that the company expects to receive CLIA certification in during first quarter 2023. The Laboratory Field Services (LFS) of California Department of Public Health (CDPH) has informed Biovica that it...
2022-12-07 08:00 Regulatory
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, OR ANY OTHER JURISDICTION...
2022-12-01 14:40
Biovica, active in cancer diagnostics, today announces that the company has employed a sales team of total of eight people to secure a fast and smooth launch and the further commercial development of DiviTum® TKa on the US market. Biovica’s...
2022-11-22 14:55
Biovica, active in cancer monitoring, today announces that the unique study design of the TK IMPACT trial, using the DiviTum® TKa blood test, will be presented as a poster at the world’s largest breast cancer symposium, SABCS, on December 8...
2022-11-22 14:50
Biovica, active in cancer monitoring, today announces that results from a study using the DiviTum® TKa blood test will be presented at the world’s largest breast cancer symposium, SABCS, on December 8. The results support using DiviTum®...
2022-11-18 11:15 Regulatory
Stockholm, Sweden, November 18, 2022 – On October 18, 2022, Biovica International AB (publ) (“Biovica” or the “Company”) (Nasdaq First North Premier Growth Market: BIOVIC B) announced that the Board of Directors resolved...
2022-11-07 14:00 Regulatory
The extra general meeting of Biovica International AB ("Biovica" or the "Company") was held today on 7 November 2022 in Stockholm and the following resolutions were passed by the meeting. RIGHTS ISSUE The extra general meeting resolved...
2022-10-20 08:00 Regulatory
Biovica, active in cancer diagnostics, today announces that Anders Morén has been appointed as the company’s Chief Financial Officer (CFO). Anders Morén will begin his new position on January 1, 2023. Most recently, Anders Morén...

>4,500

Numbers of patients in studies

28

Publications

22

Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program

No